Innocell completes Phase 3 trial on Immuncell-LC

Published: 2012-12-03 06:56:00

Updated: 2012-12-03 06:56:00

Innocell, a local biopharmaceutical company, said Thursday that it has completed its Phase 3 clinical trial on Immuncell-LC, which is an activated T-lympho therapy drug that uses the patient's own lymphocytes for the removal of residual cancer cells and prevention of its recurrence after the removal of cancer cells through surgery, embolization, etc.

The company has since June 2008 conducted...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.